187 related articles for article (PubMed ID: 36798653)
1. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.
Thirasastr P; Somaiah N
Clin Exp Gastroenterol; 2023; 16():11-19. PubMed ID: 36798653
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Symcox M; Jones RL
Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
[TBL] [Abstract][Full Text] [Related]
4. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer S; Jones RL; Blay JY; Gelderblom H; George S; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Su Y; Meade J; Wang T; Sherman ML; Ruiz-Soto R; Heinrich MC
J Clin Oncol; 2022 Dec; 40(34):3918-3928. PubMed ID: 35947817
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L
Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
Hu K; Zhang H; Shu M; Wang X
Cancer Med; 2023 Jun; 12(11):12187-12197. PubMed ID: 37084005
[TBL] [Abstract][Full Text] [Related]
7. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
Liu B; Kou Y
J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
[TBL] [Abstract][Full Text] [Related]
8. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
Front Oncol; 2022; 12():883399. PubMed ID: 35847924
[TBL] [Abstract][Full Text] [Related]
9. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
10. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study.
Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J
Front Oncol; 2023; 13():1180795. PubMed ID: 37274264
[TBL] [Abstract][Full Text] [Related]
12. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
[TBL] [Abstract][Full Text] [Related]
13. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
[TBL] [Abstract][Full Text] [Related]
14. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review.
Zhang Y; Huang Z
Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114
[No Abstract] [Full Text] [Related]
15. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
Liu WZ; Du YQ; Shen Q; Tao KX; Zhang P
J Dig Dis; 2023 Sep; ():. PubMed ID: 37706279
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours.
Golčić M; Jones RL; Huang P; Napolitano A
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627109
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Senchak J; Ahr K; von Mehren M
Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
[TBL] [Abstract][Full Text] [Related]
19. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S; George S; von Mehren M; Heinrich MC
Front Oncol; 2021; 11():672500. PubMed ID: 34322383
[TBL] [Abstract][Full Text] [Related]
20. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
